"The ongoing alignment of clinical trial regulations across APAC with global standards is significant"
BioSpectrum Asia|October 2024
Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata, a Dassault Systèmes brand headquartered in New York City and having strong presence in the United Kingdom and the Asia Pacific (APAC) region offers industry-leading expertise, analyticspowered insights, and the largest patient-level historical clinical trial data set in the world.
Ayesha Siddiqui
"The ongoing alignment of clinical trial regulations across APAC with global standards is significant"

More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. In an interaction with BioSpectrum Anthony Costello, Chief Executive Officer, Medidata shared insights on APAC clinical trial landscape, regulatory reforms and Medidata's growth strategy for the region.

Can you elaborate on Medidata’s growth strategy for the APAC region? What specific factors are driving the expansion of your business in this market?

Since entering APAC in 2005, Medidata has expanded into several key markets, including Japan, China, India, Korea, Singapore, and Australia. This growth has been driven by a deep understanding of the region’s diverse regulatory landscapes and its market dynamics and specific challenges. With each country presenting their own unique opportunities, we’ve successfully developed tailored strategies to capitalise on their changing aspects. Factors driving our expansion include the rising demand for digital innovation in clinical trials, particularly in areas such as patient centricity, trial diversity, and AI integration.

Our Medidata Unified Platform is the cornerstone of our growth, offering a comprehensive, integrated solution that streamlines the clinical trial process from start to finish. Additionally, our AI solutions, and advanced wearable and sensor technologies are meeting the increasing need for complex data capture and personalised study designs in the region.

Medidata also benefits from strong local partnerships and a legacy of innovation that positions us to quickly adapt to a rapidly evolving healthcare environment. By focusing on these areas, Medidata is well-equipped to seize new opportunities and maintain its leadership position in the APAC region.

هذه القصة مأخوذة من طبعة October 2024 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة October 2024 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BIOSPECTRUM ASIA مشاهدة الكل
BioPharma's Transformative & Strategic OUTLOOK 2025
BioSpectrum Asia

BioPharma's Transformative & Strategic OUTLOOK 2025

The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India's strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry.

time-read
10+ mins  |
December 2024
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Victor Ambros and Gary Ruvkun win 2024 Nobel Prize in Physiology or Medicine for discovery of microRNA
BioSpectrum Asia

Victor Ambros and Gary Ruvkun win 2024 Nobel Prize in Physiology or Medicine for discovery of microRNA

The Nobel Assembly at Karolinska Institutet has decided to award the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

time-read
1 min  |
BioSpectrum Asia Nov 2024
University of Hong Kong to establish Global Innovation Centre
BioSpectrum Asia

University of Hong Kong to establish Global Innovation Centre

To consolidate Hong Kong's leading position in basic research, the University of Hong Kong (HKU) is planning to establish the Global Innovation Centre (GIC), an upstream technology research facility, in Pokfulam.

time-read
1 min  |
BioSpectrum Asia Nov 2024
"Australia is a great place to do business as we have a superb research community, great partners and very experienced clinical trial units"
BioSpectrum Asia

"Australia is a great place to do business as we have a superb research community, great partners and very experienced clinical trial units"

Noxopharm Limited, an Australian biotech company, is making strides in the fight against cancer and inflammation with its innovative technology platforms, Chroma and Sofra.

time-read
5 mins  |
BioSpectrum Asia Nov 2024
"To achieve our 'Skilled India' vision, we'll train a large number of individuals quickly and to high standards"
BioSpectrum Asia

"To achieve our 'Skilled India' vision, we'll train a large number of individuals quickly and to high standards"

Jayant Singh Chaudhary, Union Minister of State (Independent Charge), Skill Development and Entrepreneurship, Government of India, in an interaction with BioSpecturm in Hyderabad, shares his insights on the various initiatives taken up by the Centre for skill development programmes, boosting self-employment.

time-read
5 mins  |
BioSpectrum Asia Nov 2024
Digital Innovations in Diabetes Care
BioSpectrum Asia

Digital Innovations in Diabetes Care

Diabetes affects 537 million people globally and is a major contributor to the non-communicable disease NCD) epidemic. Technological tools such as continuous glucose monitors CGMs) and mobile apps are redefining diabetes management. On this World Diabetes Day November 14, 2024), we explore how digital health is transforming diabetes care and the challenges associated with its integration into healthcare systems.

time-read
5 mins  |
BioSpectrum Asia Nov 2024